Biopharma Data Management Strategies to Effectively Use AI Tools
Tue, Sep 15, 2020
at 10:45 AM
ABOUT THIS WEBINAR
10:45am - 11:15 am
Convergence and Critical Mass: The Fusion Moment for Biopharma and Data The AbbVie Research Convergence Hub data sharing program between organizations was launched to correlate all R&D pipeline data, discovery data, RWD, and clinical patient data in a knowledge graph form that takes out the chemical compounds and then make it available to all (pharma, startups, universities). The goal is to create an open data science share that will ultimately help patients.
Harry Glorikian, General Partner, New Ventures Fund & Author: MoneyBall Medicine interviews:
Brian S. Martin, Head of AI R&D Information Research, Research Fellow, Abbvie
11:15am - 11:50am
Data Curation and Privacy
Belen Fraile, MD, MSC, VP & Head, US Oncology Strategic Data & Digital, Novartis Oncology Anna Langhorne, PhD, Esq, Global Privacy Counsel, Regeneron Pharmaceuticals
11:50 - 12:15
Using AI to Generate Patient Data: How Digital Twins are Shaping Clinical Trials Digital twins are AI-generated placebo patient data perfectly matched to actual trial patients. With a universal goal of being able to run better and faster clinical trials, this session will use an Alzheimer’s use case to demonstrate how digital twins can ultimately result in increased confidence in trial results.
Charles Fisher, PhD, Founder & CEO, Unlearn.AI
12:15 - 1:15
Drug Development using RWE, Integrated Research Platforms and Advanced Analyitcs/AI An interactive discussion examining the opportunities created when AI tools/technologies and digital platforms are used to evaluate global data in real time:
• Revisiting the old science of the 'parallel line'
• Getting to what a drug works on, who it works on and the level of disease it works
on using advanced analytics to evaluate the diversity of patients of whole population
• Applying AI in regulatory oversight: How regulatory centaurs present a real opportunity for faster and more accurate drug reviews
Thomas Bock, MD, MBA, Founder & Past CEO, HeritX, Inc., Chair, Healthcare Advisory Board, Columbia Business School; Former SVP, Global Head of Medical Affairs, Alexion; Co-Founder, The APANDEMIC Initiative Ülo Palm, MD, PhD, Chief Medical Officer and co-founder, Ordaos Bio; Co-Founder The APANDEMIC Initiative Peter Pitts, Former Associate Commissioner FDA, Visiting Professor, Université Paris Descartes Medical School, Chair of Innovation Management & Healthcare Performance
Tuesday, September 15, 2020 at 10:45 AM
Eastern Time (US & Canada)
Passionate about business transformations that accelerate growth, efficiency gains, cost reductions, and competitive advantage for market leaders as well as up-and-coming innovators with next-generation ideas.
Vice President and Head of Strategic Data and Digital, Novartis US Oncology
As vice president & Head of Strategic Data & Digital Oncology US, Belen Fraile leads the data analytics and digital strategy across both commercial and medical organizations, including customer experience for healthcare providers, payers,...
Charles Fisher is a scientist with interests at the intersection of physics, machine learning, and computational biology. Before founding Unlearn.AI to create artificial intelligence solutions that accelerate clinical research, Charles worked as a...
President and Co-Founder, Center for Medicine in the Public Interest; Former Associate Commissioner for External Relations, FDA, Visiting Professor, Université Paris Descartes Medical School, Chair of Innovation Management & Healthcare Performance
Unlearn has developed the first machine learning (ML) platform for creating Intelligent Control Arms with Digital Twins through its proprietary DiGenesis™ process, allowing drug developers to dramatically reduce therapy development time, while...
We connect the industry’s science minds, AI technology experts, technologists, and strategy leaders through in-person and virtual events and digital content.
Our large community of industry leaders are passionate about the work they do and are dedicated to working at the intersection of science and technology. We collaborate with our industry experts to convene engaged discussions and facilitate the translation of AI/ML technologies into patient impact.